30 results about "CD46" patented technology

It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer. Namely, a method of classifying antibodies which comprises: (1) the step of preparing a plural number of antibodies respectively recognizing cell surface antigens; (2) the step of bringing each of these antibodies into contact with a cell of the same species; (3) the step of analyzing each of the cells having been treated in the step (2) by flow cytometry and thus obtaining data indicating the reactivity of each antibody with its cell surface antigen; and (4) the step of comparing the thus obtained data and classifying the individual antibodies depending on the similarity. A method of identifying antigens which further comprises: (5) the step of selecting one to several antibodies from each antibody group formed in the step (4) and identifying antigens thereof; and (6) on the assumption that antigens of the antibodies belonging to a single antibody group are the same or highly related to one another, making relations between the antigens having been identified in the step (5) and the antibody groups to thereby identify the antigens. An antibody against HER1, an antibody against HER2, an antibody against CD46, an antibody against ITGA3, an antibody against ICAM1, an antibody against ALCAM, an antibody against CD147, an antibody against C1qR, an antibody against CD44, an antibody against CD73, an antibody against EpCAM and an antibody against HGFR, each obtained by using the above methods.

Provided are non-human animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and autoimmune diseases such as diseases of the central nervous system, including multiple sclerosis (MS), and diabetes. Such non-human animal model systems may be suitably employed for the study of diseases such as MS and diabetes and for the identification and characterization of candidate therapeutic compounds and compositions for the treatment of such diseases. Also provided herein are markers and methods for the detection, in patients susceptible to autoimmune disease, of autoimmune diseases of the central nervous system such as progressive multifocal leukoencephalopathy (PML) following treatment with one or more therapeutic agent as exemplified herein by the therapeutic agent natalizumab. Exemplary animal model systems comprise marmosets infected with a herpesvirus such as HHV6-A and HHV6-B, transgenic mouse and zebrafish animal model systems wherein the transgene encodes CD46, and methods for monitoring the risks of patients having MS, diabetes and other auto-immune disorders treated with anti-adhesion molecules such as natalizumab.

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.

Adenoviral vectors which effectively transduce primary tumor cells are provided. The adenoviral vectors comprise a chimeric adenovirus fiber protein which includes at least a portion of a Subgroup C adenovirus fiber shaft and at least a portion of a Subgroup B adenovirus or serotype 37 adenovirus head, wherein the head region binds CD46.

An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.

The present invention relates to methods of cancer therapy using subcutaneous administration of antibody-drug conjugates (ADCs). Preferably, the ADC comprises an antibody that binds to Trop-2, CEACAM5, CEACAM6, CD20, CD22, CD30, CD46, CD74, Her-2, folate receptor, or HLA-DR. More preferably, the drug is SN-38. Subcutaneous administration is at least as effective as intravenous administration of the same ADC. Surprisingly, subcutaneous administration can be used without inducing unmanageable adverse local toxicity at the injection site. Subcutaneous administration is advantageous in requiring less frequent administration, substantially reducing the amount of time required for intravenous administration, and reducing the levels of systemic toxicities observed with intravenous administration. When administered at specified dosages and schedules, the ADCs can reduce solid tumors in size, reduce or eliminate metastases and are effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

The embodiments of the present invention provide a bispecific chimeric antigen receptor, consisting of a signal peptide, two specific antigen-binding fragments, an extracellular spacer region, a transmembrane region, an intracellular co-stimulatory signaling domain, the first antigen that is recognized and bound by the specific antigen-binding fragments is a member selected from the group consisting of CD19, CD20, CD22, CD33, CD269, CD138, CD79a, CD79b, CD23, ROR1, CD30, B cell surface antibody light chain, CD44, CD123, Lewis Y, CD7 and CD46; the second antigen that is recognized and bound by the specific antigen-binding fragments is CD38, the two specific antigen-binding fragments is linked by a linker peptide, the bispecific chimeric antigen receptor can recognize respectively two kinds of tumor-associated antigens by constructing low affinity chimeric antigen receptors and high affinity chimeric antigen receptors and have very strong specificity. In addition, the embodiments of the present invention also provide a use of the bispecific chimeric antigen receptor in the treatment of tumors.

This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and / or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.

The invention provides a genetically engineered bacterium capable of expressing cell-penetrating peptide fusion protein and application. The genetically engineered bacterium E.coli BL21 / pET-32a-CSFR with CCTCC NO: M2014631. The strain can be used for expressing protein transduction domain polypeptide (PEP-1) and hog cholera virus acceptor (CD46) genetically engineered fusion protein PEP-1-CD46. The genetically engineered bacterium has the advantages of large expression amount, soluble protein, low cost and high safety. The expressed PEP-1-CD46 protein can be used as mediated protein of hog cholera virus penetrating a cell membrane, so that the virus titer of hog cholera virus can be improved, and the defect that the virus content in a current hog cholera virus cell vaccine is low and cannot achieve the standard of vaccine preparation can be overcome.

The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Cc17, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.

The inventors developed novel pseudotyped lentiviral vector particles comprising a morbillivirus fusion (F) protein and a mutated hemagglutinin (H) protein of the measles virus (MeV) or the Edmonton strain of the measles virus (MeVEdm), wherein the cytoplasmic portions of the F and the H protein are truncated, and wherein the amino acids necessary for receptor recognition in the H protein are mutated that it does not interact with CD46, SLAM and / or nectin-4 and further has a single chain antibody to a cell surface marker of hESCs and iPSCs at its ectodomain. In this invention, the single chain variable fragment (scFv) anti-cell surface marker coding sequence of the single chain antibody is fused to the coding sequence at the ectodomain of the H protein, wherein the single chain antibody is selected from the group consisting of CD30, EpCAM (CD326), CD9, Thy-1 (CD90), SSEA-3, SSEA-4, TRA-1-60 or TRA-1-81. The transduction according to the present invention does not interfere with the pluripotency, i.e. present transduced hESCs and iPSCs remain undifferentiated, i.e. are able differentiate into all germ layer lineages.

Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCF1 (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIG1, OLIG2, ADORA3, CLC, and SLC29A1 (group II); and CBS and ARG1 (group IV).

This disclosure relates to methods for detecting a level of expression of one or more genes (or proteins) in a subject having or suspected of having cancer, and optionally treating the subject with anadenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist, to treat the cancer. The genes (or proteins) include, without limitation, CD68, CD163, LBP, CCL2, CCL3, CCL7,CCL24, CCNE1, CD 14, CD300E, CD86, CD93, CLEC5A, CSF3, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, DFNA5, ECEL1, EPB41L3, EHF, FUT7, GALM, GBP6, GPR157, HAS1, IL1A, IL-1[beta], IL23, IL24, IL5, IL6, IL8, INHBA, LAP3, LAYN, LOC100505585, MRPL11, NID1, OST4, PADI2, PID1, PLAUR, PPBP, PTGS2, RHCG, SERPINB2, SLC11A1, SLC7A7, SPON1, ST6GALNAC2, TBX21, THBS1, C1R, C1S, C4BPA, CCL11, CCL20, CXCL16, CXCL2,HAMP, HSD11B1, ITGAM, LIF, SAA1, TFRC, TLR5, TNFSF14, TREM2, APP, ATG10, BCL2, CCL15, CD24, CD46, CD59, CREB5, CX3CL1, CXCL14, CYFIP2, DEFB1, DPP4, ECSIT, EPCAM, IFIT1, IGF1R, ITGA6, ITGB3, MAP2K4, MAPK1, MASP1, PPARG, RORC, SPA17, STAT5B, TOLLIP, AKT3, BMI1, CD 164, CD34, CDH5, CREB1, DOCK9, ENG, HMGB1, ITGA1, JAM3, MAF, MAPK3, MAPK8, MCAM, MFGE8, NOTCH1, NRP1, PRKCE, SMAD2, TAL1, THY1, TNFSF12,TRAF6, TXNIP, VEGFA, S100A8, and / or WDR83OS.

The present invention relates to a transgenic cloned pig for xenotransplantation in which porcine endogenous retrovirus (RUN) EnvC is negative, α1,3-galactosyltransferase (GGTA1), CMP-N-acetylneuraminic acid hydroxylase (CMAH), isoglobotrihexosylceramide synthase (iGb3s), and beta-I,4-N-acetyl-galactosaminyl transferase2 (β4GalNT2) are knocked out, and human CD46 and thrombomodulin (TBM) genes are expressed, and to a method of preparing the transgenic cloned pig. The transgenic cloned pig according to the present invention may overcome hyperacute and antigen-antibody mediated immune rejection reaction, immune rejection reaction due to blood coagulation, and immune rejection reaction due to complement activity, without causing transfer of porcine endogenous retrovirus that occurs in xenotransplantation. Therefore, the transgenic cloned pig according to the present invention may be usefully utilized as a donor animal for xenotransplantation of organs and cells.

The present invention provides a genetically engineered bacterium expressing a membrane-penetrating peptide fusion protein and its application. The present invention provides a genetically engineered bacterium, E. coli BL21 / pET‑32a-CSFR, CCTCC NO: M2014631. The strain can express protein transduction domain polypeptide (PEP‑1) and classical swine fever virus receptor (CD46) genetically engineered fusion protein PEP‑1‑CD46. Its advantages are large expression, soluble protein, low cost and good safety. The expressed PEP‑1‑CD46 protein can be used as a mediating protein for CSFV to cross the cell membrane, improve the virus titer of CSFV in cell culture, and solve the problem that the current CSFV cell vaccine has a low virus content and cannot meet the vaccine standard Shortcomings.

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46-overexpressing tumors.

This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct adenovirus infection specifically to cells having said cell surface molecule on their surface. The invention relates to nucleic acid sequences encoding fusion proteins comprising a) a polypeptide derived from the extracellular domain of CD46 and b) a heterologous polypeptide, methods for the production of the modified polypeptides and suitable recombinant expression vectors and host cells. Pharmaceutical compositions comprising the modified polypeptide of the invention are useful together with recombinant, genetically engineered adenovirus of subtype B for the treatment and prophylaxis of disorders and diseases, like cancer.

The invention discloses a plecoglossus altivelis CD46 gene, a recombinant engineering bacterium and a preparation method of a polyclonal antibody of the CD46 gene. The plecoglossus altivelis CD46 geneis characterized in that the plecoglossus altivelis CD46 gene comprises plecoglossus altivelis CD46-1, CD46-2 and CD46-3 genes, and the cDNA sequences are shown as SEQID NO.1, SEQID NO.3 and SEQID NO.5 correspondingly. The preparation method of the recombinant plecoglossus altivelis CD46 gene engineering bacterium comprises the following steps: constructing a recombinant plecoglossus altivelis CD46 protein extracellular region pichia pastoris expression plasmid; screening a high-expression recombinant engineering strain; culturing the high-expression yeast strain in a fermentation tank; purifying the recombinant plecoglossus altivelis CD46 extracellular region protein to obtain a recombinant plecoglossus altivelis CD46 gene engineering bacterium; and preparing a rabbit anti-plecoglossus altivelis CD46 protein polyclonal antibody through a rabbit immunization method. The advantage is that a plecoglossus altivelis CD46 protein isomer can be specifically recognized.

The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Ccl7, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3gal6, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.

The invention relates to macropinocytosis human anti-CD46 antibodies and targeted cancer therapies. In various embodiments, provided are human anti-CD46 antibodies that internalize via the macropinocytosis pathway and enter tumor cells, as well as antibody-drug conjugates (ADC) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46 over-expressing tumors.

The present disclosure relates to methods for detecting expression levels of one or more genes in a subject having or suspected of having a cancer and optionally treating the subject with an adenosine pathway antagonist (e.g., an adenosine A2A receptor (ADORA2A) antagonist) in combination with a PD-1 inhibitor and / or a PD-L1 inhibitor to treat the cancer. The genes comprise, but are not limited to, CD68, CD163, LBP, CCL2, CCL3,CCL7,CCL24,CCNE1,CD14,CD300E,CD86,CD93,CLEC5A, CSF3,CXCL1,CXCL2,CXCL3,CXCL5,CXCL6,CXCL8,DFNA5,ECEL1,EPB41L3,EHF,FUT7,GALM,GBP6,GPR157,HAS1,IL1A,IL-1beta,IL23,IL24,IL5,IL6,IL8,INHBA,LAP3,LAYN,LOC100505585,MRPL11,NID1,OST4,PADI2,PID1,PLAUR,PPBP,PTGS2,RHCG,SERPINB2,SLC11A1,SLC7A7,SPON1,ST6GALNAC2,TBX21,THBS1,C1R,C1S,C4BPA,CCL11,CCL20,CXCL16,CXCL2,HAMP,HSD11B1,ITGAM,LIF,SAA1,TFRC,TLR5,TNFSF14,TREM2,APP,ATG10,BCL2,CCL15,CD24,CD46,CD59,CREB5,CX3CL1,CXCL14,CYFIP2,DEFB1,DPP4,ECSIT,EPCAM,IFIT1,IGF1R,ITGA6,ITGB3,MAP2K4,MAPK1,MASP1,PPARG,RORC,SPA17,STAT5B,TOLLIP,AKT3,BMI1,CD164,CD34,CDH5,CREB1,DOCK9,ENG,HMGB1,ITGA1,JAM3,MAF,MAPK3,MAPK8,MCAM,MFGE8,NOTCH1,NRP1,PRKCE,SMAD2,TAL1, THY1, TNFSF12,TRAF6, TXNIP,VEGFA,S100A8 and / or WDR83OS.

The invention discloses a fusion protein, and belongs to the biopharmaceutical technical field. The fusion protein is a fusion protein obtained by fusion of a regulatory protein CD46 and a regulatoryprotein CD55.

This disclosure relates to methods for detecting a level of expression of one or more genes (or proteins) in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist, to treat the cancer. The genes (or proteins) include, without limitation, CD68, CD163, LBP, CCL2, CCL3, CCL7, CCL24, CCNE1, CD 14, CD300E, CD86, CD93, CLEC5A, CSF3, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, DFNA5, ECEL1, EPB41L3, EHF, FUT7, GALM, GBP6, GPR157, HAS1, IL1A, IE-1β, 1L23, 1L24, IL5, 1L6, 1L8, INHBA, LAP3, LAYN, LOC100505585, MRPL11, NID1, OST4, PADI2, PID1, PLAUR, PPBP, PTGS2, RHCG, SERPINB2, SLC11A1, SLC7A7, SPON1, ST6GALNAC2, TBX21, THBS1, C1R, C1S, C4BPA, CCL11, CCL20, CXCL16, CXCL2, HAMP, HSD11B1, IT GAM, LIF, SAA1, TFRC, TLR5, TNFSF14, TREM2, APP, ATG10, BCL2, CCL15, CD24, CD46, CD59, CREB5, CX3CL1, CXCL14, CYFIP2, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

The invention discloses a substance for improving the lethality of immune cells as well as a preparation and application of the substance. The substance for improving the lethality of immune cells comprises one or more of berberine, benzoyloxypaeoniflorin, methylophiopogonone A, canadin(tetrahydroberberine), leucoside(kaempferol 3-O-sambubioside), cheilanthifoline, bucuculline, sibirioside A, harpagide, dendrobine, coptisine hydrochloride, coptisine, norisoboldine, ginsenoside Rg3, 3,5-Dicaffeoyl quinic acid, L-arginine, 3-O-feruloylquinic acid, lucidone, atractyloside A, ginsenoside Rh3, Cholan-24-oic acid, oleuropein, parishin A, parishin B, p-hydroxyphenylethyl trans-ferulate, Palbinone, pseudo-ginsenoside RT1, pimpinellin, 4-hydroxybenzoic acid, Eburicoic acid, alismoxide and alpha-cyperone. According to the substance disclosed by the invention, immunity-related genes such as CD46, MUC16, TGF-beta and the like and GAST and SS18 are selected as direct or indirect regulation and control target genes from genes of which the expression quantity is obviously changed in transcriptome analysis data.

The invention provides a real-time fluorescence LAMP detection method for specific expression human CD46 transgenic pigs and a kit. Real-time fluorescence LAMP detection is carried out on specific expression human CD46 transgenic pigs by screening six specific primers, and a detection system and reaction conditions are optimized. The method is applicable to on-site rapid screening, closed tube detection is carried out fluorescence amplification signals, cover opening operation after the reaction is avoided, the aerosol pollution risk is lowered, and false positive occurrence possibility is greatly reduced; meanwhile, reaction time is shortened, and a judgment result can be obtained within 45 min.

This disclosure relates to methods for detecting a level of expression of one or more genes in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist in combination with a PD-1 inhibitor and / or a PD-L1 inhibitor, to treat the cancer. The genes include, without limitation, CD68, CD 163, EBP, CCL2, CCL3, CCL7, CCL24, CCNE1, CD 14, CD300E, CD86, CD93, CLEC5A, CSF3, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, DFNA5, ECEL1, EPB41L3, EHF, FUT7, GALM, GBP6, GPR157, HAS1, IL1A, IE-1β, IL23, IL24, IL5, IL6, IL8, INHBA, LAP3, LAYN, LOC100505585, MRPL11, NID1, OST4, PADI2, PID1, PLAUR, PPBP, PTGS2, NRHCG, SERPINB32, SLC11A1, SLC7A7, SPON1, ST6GALNAC2, TBX21, THBS1, C1R, C1S, C4B3PA, CCL11, CCL20, CXCL16, CXCL2, HAMP, HSD11B1, IT GAM, LIF, SAA1, TFRC, TLR5, TNFSF14, TREM2, APP, ATG10, BCL2, CCL15, CD24, CD46, CD59, CREB5, CX3CL1, CXCL14, CYFIP2, DEFB1, DPP4, EC SIT, EPCAM, IFIT1, IGF1R, ITGA6, ITGB3, MAP2K4, MAPK1, MASP1, PPARG, RORC, SPA17, STAT5B, TOLLIP, AKT3, BMI1, CD 164, CD34, CDH5, CREB1, DOCK9, ENG, HMGB1, ITGA1, JAM3, MAF, MAPK3, MAPK8, MCAM, MFGE8, NOTCH1, NRP1, PRKCE, SMAD2, TAL1, THY1, TNFSF12, TRAF6, TXNIP, VEGFA, S100A8, and / or WDR83 OS.

The invention provides a real-time fluorescence LAMP detection method for specific expression human CD46 transgenic pigs and a kit. Real-time fluorescence LAMP detection is carried out on specific expression human CD46 transgenic pigs by screening six specific primers, and a detection system and reaction conditions are optimized. The method is applicable to on-site rapid screening, closed tube detection is carried out fluorescence amplification signals, cover opening operation after the reaction is avoided, the aerosol pollution risk is lowered, and false positive occurrence possibility is greatly reduced; meanwhile, reaction time is shortened, and a judgment result can be obtained within 45 min.